Global Neuromodulation Market Expected to Expand with a CAGR of Over 11% During the Forecast Period, 2020-2024 - ResearchAndMarkets.com

The "Neuromodulation Market by Product and Geography - Forecast and Analysis 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Global Neuromodulation Market: About this market

Thw neuromodulation market analysis considers sales from implantable neuromodulation devices and external neuromodulation devices. Our study also finds the sales of neuromodulation in Asia, Europe, North America, and ROW. In 2019, the implantable neuromodulation devices segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as technological advances and new product launches will play a significant role in the implantable neuromodulation devices segment to maintain its market position. Also, our global neuromodulation market report looks at factors such as increasing prevalence of chronic diseases and related risk factors, increasing awareness initiatives and access to healthcare, and technological advances. However, high cost of devices and procedures, device limitations and complications, and stringent regulations may hamper the growth of the neuromodulation industry over the forecast period.

Global Neuromodulation Market: Overview

Technological advances

Technological advances related to battery longevity and miniaturization of implantable neuromodulation devices, including the circuitry and battery, device software and programming, introduction of rechargeable batteries, and implantation techniques, have significantly improved the reliability and effectiveness of neuromodulation devices. One of the latest technological advances in neuromodulation devices has been the development of MRI-conditional implantable neuromodulation devices. Such technological advances will lead to the expansion of the global neuromodulation market at a CAGR of over 11% during the forecast period.

Expanding indications

Several neuromodulation devices have recently received approval for indications and are ongoing clinical trials to explore their additional therapeutic properties. Some new indications that are currently being investigated for neuromodulation therapy include Alzheimer's, heart failure, stroke recovery, diabetic neuropathy, migraine headaches, refractory angina relief, hypertension, chronic respiratory insufficiency, and gastrointestinal disorders. Historically, neuropathic pain conditions have been difficult to treat as the pain stem from tissue and nerve damages or result from a disruption in how the peripheral and central nervous system processes or transmit pain signals. This development is expected to have a positive impact on the overall market growth.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

• Preface
• Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis
• Value chain analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2019
• Market Outlook
• Market size and forecast 2019-2024

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

• Market segmentation by product
• Comparison by product
• Implantable neuromodulation devices - Market size and forecast 2019-2024
• External neuromodulation devices - Market size and forecast 2019-2024
• Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2019-2024
• Europe - Market size and forecast 2019-2024
• Asia - Market size and forecast 2019-2024
• ROW - Market size and forecast 2019-2024
• Key leading countries
• Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

• Market drivers
• Market challenges

PART 11: MARKET TRENDS

• Improving reimbursement policies
• Strategic collaborations and acquisitions
• Expanding indications

PART 12: VENDOR LANDSCAPE

• Overview
• Landscape disruption
• Competitive scenario

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Abbott Laboratories
• Boston Scientific Corp.
• LivaNova Plc
• Medtronic Plc
• NeuroMetrix Inc.
• Neuronetics Inc.
• Nevro Corp.
• Nuvectra Co.
• OMRON Corp.
• Zynex Inc.

For more information about this report visit https://www.researchandmarkets.com/r/mggdr7

View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005359/en/